Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health.
We have a successful heritage in developing pharmaceutical products, including CRINONE® 8% (progesterone gel), which is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and Allergan, Inc. in the U.S.
We are uniquely positioned to leverage the pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services to advance our proprietary therapeutics, while also providing valuable consultative services to our pharmaceutical industry customers.
We are currently developing several product candidates that utilize our proprietary intravaginal ring (IVR) technology. We expect to initiate our first clinical trial for this technology with JNP-0101, an oxybutynin IVR for the treatment of overactive bladder, in 2017.
With a highly experienced leadership team, a strong balance sheet and positive cash flows from our core business, all of which support the development of our product pipeline, we are well positioned for continued success.